|Snake oil salesmen are alive and well in the 2000's.|
They know how to use the Congress to overturn FDA new
review panel recommendations and market away.
Bad Science is simply not doing science right. If you cut corners, never repeat experiments to confirm they are reproducible, bury negative results, then you can end up with egg on your face as a scientist. At best, the target for teasing by your colleagues, or at worst a biomedical company that contributes to the illness or deaths of many people and who will never be trusted again in the science or medical world. As it should be.
Bad science or medicine seems to happen when money is part of the motivation equation in the form of "for profit". Unfortunately, that is the context where most commercial Pharma research occurs, including clinical trials. With shareholders to pay, there is a strong executive pressure to get the product developed and flying out of the pharmacy on Doctor's prescription pads as soon as possible. This factor, profits, are one of the greatest conflicts of interest (COI) we must manage.
For all of us, as the patient, this can have bad consequences. For our Doctors, they may be making prescription decisions based on information that is skewed or incomplete. They can be in a position where they cannot even get the full story on many of the drugs they must choose from. The Pharmacist will be in the same position as your Doctor. The problem that is keeping all three of us in the dark is reporting bias on the part of the drug developer. That is, under-reporting of negative trial results, and basic cherry-picking of trial results. While we have currently, in the United States, a political effort to reduce government regulations, we already suffer commercial lobbying and political overriding of FDA biomedical science recommendations on drug approvals. This includes ignoring expert panel recommendations to not approve a drug and instead let the company market away. Essentially neutering the ability of the FDA to save us all from snake oil salesmen, even in 2018.